Early measurable residual disease clearance is linked to better outcomes in acute myeloid leukemia, study suggests.
Zacks Small Cap Research on MSN1d
INAB: Introducing INB-600, A γδ T Cell Engager PlatformINAB READ THE FULL INAB RESEARCH REPORT Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc ...
Increased mixed chimerism, as detected by AlloHeme, could predict post-transplant relapse “with a high degree of accuracy,” said Monzr M. Al Malki, MD.
Clinical Trials Arena on MSN5d
Cantargia enrols first patient in trial of nadunolimab for AML and MDSSwedish company Cantargia has enrolled the first patient in the Phase Ib/IIa trial of nadunolimab for treating individuals ...
The new findings are the first to describe distributions and perturbations of low-density granulocyte and normal-density ...
Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease ...
Open label study in forty AML and MDS patients Study financed by the US Department of Defense Cantargia (Cantargia AB; Nasdaq ...
Actinium Pharmaceuticals (ATNM) announced that results from the clinical trial evaluating Actimab-A in combination with the chemotherapy CLAG-M ...
In March 2025, Akeso initiated an open-label, Phase Ib/II study involving patients diagnosed with acute myeloid leukemia (AML ...
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback